Cargando…

Antineoplastics Encapsulated in Nanostructured Lipid Carriers

Ideally, antineoplastic treatment aims to selectively eradicate cancer cells without causing systemic toxicity. A great number of antineoplastic agents (AAs) are available nowadays, with well-defined therapeutic protocols. The poor bioavailability, non-selective action, high systemic toxicity, and l...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodrigues da Silva, Gustavo Henrique, de Moura, Ludmilla David, de Carvalho, Fabíola Vieira, Geronimo, Gabriela, Mendonça, Talita Cesarim, de Lima, Fernando Freitas, de Paula, Eneida
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8619566/
https://www.ncbi.nlm.nih.gov/pubmed/34834022
http://dx.doi.org/10.3390/molecules26226929
_version_ 1784605024089800704
author Rodrigues da Silva, Gustavo Henrique
de Moura, Ludmilla David
de Carvalho, Fabíola Vieira
Geronimo, Gabriela
Mendonça, Talita Cesarim
de Lima, Fernando Freitas
de Paula, Eneida
author_facet Rodrigues da Silva, Gustavo Henrique
de Moura, Ludmilla David
de Carvalho, Fabíola Vieira
Geronimo, Gabriela
Mendonça, Talita Cesarim
de Lima, Fernando Freitas
de Paula, Eneida
author_sort Rodrigues da Silva, Gustavo Henrique
collection PubMed
description Ideally, antineoplastic treatment aims to selectively eradicate cancer cells without causing systemic toxicity. A great number of antineoplastic agents (AAs) are available nowadays, with well-defined therapeutic protocols. The poor bioavailability, non-selective action, high systemic toxicity, and lack of effectiveness of most AAs have stimulated the search for novel chemotherapy protocols, including technological approaches that provide drug delivery systems (DDS) for gold standard medicines. Nanostructured lipid carriers (NLC) are DDS that contain a core of solid and lipid liquids stabilised by surfactants. NLC have high upload capacity for lipophilic drugs, such as the majority of AAs. These nanoparticles can be prepared with a diversity of biocompatible (synthetic or natural) lipid blends, administered by different routes and functionalised for targeting purposes. This review focused on the research carried out from 2000 to now, regarding NLC formulations for AAs (antimetabolites, antimitotics, alkylating agents, and antibiotics) encapsulation, with special emphasis on studies carried out in vivo. NLC systems for codelivery of AAs were also considered, as well as those for non-classical drugs and therapies (natural products and photosensitisers). NLC have emerged as powerful DDS to improve the bioavailability, targeting and efficacy of antineoplastics, while decreasing their toxic effect in the treatment of different types of cancer.
format Online
Article
Text
id pubmed-8619566
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-86195662021-11-27 Antineoplastics Encapsulated in Nanostructured Lipid Carriers Rodrigues da Silva, Gustavo Henrique de Moura, Ludmilla David de Carvalho, Fabíola Vieira Geronimo, Gabriela Mendonça, Talita Cesarim de Lima, Fernando Freitas de Paula, Eneida Molecules Review Ideally, antineoplastic treatment aims to selectively eradicate cancer cells without causing systemic toxicity. A great number of antineoplastic agents (AAs) are available nowadays, with well-defined therapeutic protocols. The poor bioavailability, non-selective action, high systemic toxicity, and lack of effectiveness of most AAs have stimulated the search for novel chemotherapy protocols, including technological approaches that provide drug delivery systems (DDS) for gold standard medicines. Nanostructured lipid carriers (NLC) are DDS that contain a core of solid and lipid liquids stabilised by surfactants. NLC have high upload capacity for lipophilic drugs, such as the majority of AAs. These nanoparticles can be prepared with a diversity of biocompatible (synthetic or natural) lipid blends, administered by different routes and functionalised for targeting purposes. This review focused on the research carried out from 2000 to now, regarding NLC formulations for AAs (antimetabolites, antimitotics, alkylating agents, and antibiotics) encapsulation, with special emphasis on studies carried out in vivo. NLC systems for codelivery of AAs were also considered, as well as those for non-classical drugs and therapies (natural products and photosensitisers). NLC have emerged as powerful DDS to improve the bioavailability, targeting and efficacy of antineoplastics, while decreasing their toxic effect in the treatment of different types of cancer. MDPI 2021-11-17 /pmc/articles/PMC8619566/ /pubmed/34834022 http://dx.doi.org/10.3390/molecules26226929 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Rodrigues da Silva, Gustavo Henrique
de Moura, Ludmilla David
de Carvalho, Fabíola Vieira
Geronimo, Gabriela
Mendonça, Talita Cesarim
de Lima, Fernando Freitas
de Paula, Eneida
Antineoplastics Encapsulated in Nanostructured Lipid Carriers
title Antineoplastics Encapsulated in Nanostructured Lipid Carriers
title_full Antineoplastics Encapsulated in Nanostructured Lipid Carriers
title_fullStr Antineoplastics Encapsulated in Nanostructured Lipid Carriers
title_full_unstemmed Antineoplastics Encapsulated in Nanostructured Lipid Carriers
title_short Antineoplastics Encapsulated in Nanostructured Lipid Carriers
title_sort antineoplastics encapsulated in nanostructured lipid carriers
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8619566/
https://www.ncbi.nlm.nih.gov/pubmed/34834022
http://dx.doi.org/10.3390/molecules26226929
work_keys_str_mv AT rodriguesdasilvagustavohenrique antineoplasticsencapsulatedinnanostructuredlipidcarriers
AT demouraludmilladavid antineoplasticsencapsulatedinnanostructuredlipidcarriers
AT decarvalhofabiolavieira antineoplasticsencapsulatedinnanostructuredlipidcarriers
AT geronimogabriela antineoplasticsencapsulatedinnanostructuredlipidcarriers
AT mendoncatalitacesarim antineoplasticsencapsulatedinnanostructuredlipidcarriers
AT delimafernandofreitas antineoplasticsencapsulatedinnanostructuredlipidcarriers
AT depaulaeneida antineoplasticsencapsulatedinnanostructuredlipidcarriers